Mr Chris Buyse (42) brings to ThromboGenics more than 18 years experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign where he co-ordinated its acquisition by BASF earlier this year. Before this, Mr Buyse was Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world's largest telecom companies, and was CFO and interim CEO of Keyware Technologies, reporting to the President of the Board. In addition, he held several financial positions as financial controller and internal auditor at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever.
Prof. Desiré Collen, CEO of ThromboGenics said: "Andrew joined to help execute the IPO and on behalf of the executive management team and the Board of Directors, I would like to thank Andrew for all his work and the crucial role he played during our recent IPO on Eurolist of Euronext Brussels. We wish him well for his future endeavours. We are very pleased to welcome Chris to ThromboGenics and I am confident he will be a valuable asset as we look to build both our business and our relationships with investors and analysts."
Andrew Guise commented: "It has been a very interesting time to work with ThromboGenics. I am glad that I was able to help complete the IPO process and that we have found a strong candidate to be able to take the Company on to the next stage of its evolution."
Commenting on his new appointment, Mr Buyse said: "ThromboGenics is a biotechnology company with great potential. I am really looking forward to building on its recent successful IPO to create significant value to its shareholders as the company grows into a leading company focused on vascular disease."
For further information please contact: ThromboGenics Prof. Désiré Collen, CEO Tel: +32 (0) 16 34 61 94 Citigate Dewe Rogerson David Dible / Valerie Auffray Tel: (0) 207 638 95 71
About ThromboGenics
ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for acute stroke and peripheral arterial occlusive disease. ThromboGenics also has five other drug candidates in preclinical development with preclinical proof-of-principle demonstrated, including TB-402 (Anti-Factor VIII) and TB-403 (Anti-PlGF). The Company has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Ireland and the U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com
